Iovance Biotherapeutics reported a net loss of $113.0 million for the first quarter of 2024, with revenue of $0.7 million from Proleukin sales. The company highlighted the strong initial demand for Amtagvi, with over 100 patients enrolled across more than 40 authorized treatment centers.
Amtagvi U.S. launch is off to a strong start following FDA approval.
Over 100 patients have enrolled for Amtagvi therapy across more than 40 authorized treatment centers.
Amtagvi regulatory submissions are on track in the EU, UK, and Canada for 2024.
Iovance is ramping up the U.S. launch throughout 2024 with additional ATCs.
Iovance anticipates continued strong launch momentum for Amtagvi in the U.S. throughout 2024 and is progressing with regulatory submissions in Europe and Canada.
Analyze how earnings announcements historically affect stock price performance